On Jun, 29 Recro Pharma, Inc. (REPH) Hit 12-Month Low at $4.91

June 29, 2018 - By Gwen Gough

Recro Pharma, Inc. (NASDAQ:REPH) Corporate Logo

Big Money Sentiment increased to 2.37 in Q1 2018. It has change of 0.87, from 2017Q4’s 1.5. The ratio improved due to Recro Pharma, Inc. positioning: 5 sold and 14 reduced. 23 funds took stakes and 22 increased stakes. Investors holded 9.57 million in 2017Q4 but now own 10.95 million shares or 14.40% more.
Germany-based Deutsche Retail Bank Ag has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Brandywine Global Inv Lc accumulated 0% or 41,500 shs. Essex Invest Management Com Llc holds 145,614 shs or 0.21% of its capital. Comml Bank Of Montreal Can holds 4,328 shs or 0% of its capital. Dimensional Fund L P invested in 0% or 124,115 shs. State Of Wisconsin Inv Board reported 11,000 shs. Comml Bank Of Mellon Corporation has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). Manufacturers Life Ins The has 235,712 shs for 0% of their capital. Ameritas Prns owns 1,196 shs for 0% of their capital. Morgan Stanley has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). 44,200 are held by Bailard. Jacobs Levy Equity Mgmt reported 40,264 shs. Balyasny Asset Mgmt accumulated 13,967 shs or 0% of the stock. Barclays Public Limited Com holds 0% or 4,974 shs in its capital. California Public Employees Retirement System has 64,300 shs.

Recro Pharma, Inc. had 7 sales and 0 buys since January 2, 2018. This’s net activity of $3.70 million. Another trade for 12,964 shs valued at $115,139 was sold by SCP Vitalife Partners (Israel) II – L.P.. The insider SCP Vitalife Partners II LP sold 38,810 shs worth $344,688. On Friday, March 9 Berelowitz Michael also sold $78,347 worth of Recro Pharma, Inc. (NASDAQ:REPH).

A yearly low was hit by Recro Pharma, Inc. (NASDAQ:REPH). Today’s price per share was $4.91. It’s 7.00 % below our $4.57. It was reported on Jun, 29 by Barchart.com. Recro Pharma, Inc. (NASDAQ:REPH) has $100.69 million market cap. At $4.57 price target, the company’s valuation could be $7.05M less.

The stock increased 2.29% or $0.11 during the last trading session, touching $4.91.Currently Recro Pharma, Inc. is downtrending after 32.73% change in last June 29, 2017. REPH has 86,938 shares volume. The stock underperformed the S&P 500 by 45.30%.

Recro Pharma, Inc. (NASDAQ:REPH)’s quarterly earnings will be reported on August, 9., according to Faxor. Analysts have expectation on stock’s EPS of $-1.35. That’s down 181.25 % from last year’s $-0.48 EPS. 107.69 % negative EPS growth is what analysts predict. $-0.65 EPS was reported for previous quarter.

Recro Pharma, Inc. (NASDAQ:REPH) Ratings Coverage

In total 4 analysts cover Recro Pharma (NASDAQ:REPH). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. (NASDAQ:REPH) has 100% bullish analysts. With $21.2500 highest and $1100 lowest price target, Recro Pharma has $15.81 average price target or 222.00% above the current ($4.91) price. 5 are the (NASDAQ:REPH)’s ratings reports on Jun 29, 2018 according to StockzIntelligence Inc. On Wednesday, February 28 the firm has “Buy” rating by Piper Jaffray given. The company rating was initiated by Berenberg on Thursday, April 19. On Tuesday, February 13 the stock has “Buy” rating by Oppenheimer. On Thursday, May 10 the company was maintained by Oppenheimer.

For more Recro Pharma, Inc. (NASDAQ:REPH) news announced briefly go to: Globenewswire.com, Digitaljournal.com, Globenewswire.com, Streetinsider.com or Globenewswire.com. The titles are as follows: “Pomerantz Law Firm Announces the Filing of a Class Action against Recro Pharma, Inc. and Certain Officers – REPH” announced on May 31, 2018, “Recro Pharma ALERT NOTICE: Pawar Announces Important July 30, 2018 Lead Plaintiff Deadline in Class Action …” on June 26, 2018, “REPH LOSS NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Recro Pharma, Inc …” with a publish date: June 02, 2018, “Recro Pharma (REPH) Reports Publication of Phase III IV Meloxicam Abdominoplasty Data in Plastic and …” and the last “SHAREHOLDER ALERT – FLR REPH TAL HAIR: The Law Offices of Vincent Wong Reminds Investors of Important …” with publication date: June 26, 2018.

Recro Pharma, Inc., a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States.The firm is worth $100.69 million. The Company’s lead product candidate includes injectable meloxicam, which completed pivotal Phase III clinical trials for the treatment of post-operative pain.Currently it has negative earnings. The firm also provides Dex-IN, an intranasal formulation of dexmedetomidine that is in development stage for treating post-operative pain and peri-procedural pain; and Fadolmidine, alpha-2 agonist product for use in treating neuropathic pain.

Recro Pharma, Inc. (NASDAQ:REPH) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: